Last reviewed · How we verify
NCT06903299
Prospective Investigation of Intra-Articular Tranexamic Acid Use in Elective Hip Arthroplasty
trial testing Intra-articular Tranexamic acid application in Blood Loss in 1,000 participants. Currently enrolling.
31 December 2026
Quick facts
| Lead sponsor | St. Anne's University Hospital Brno, Czech Republic |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 1,000 |
| Start date | 1 January 2023 |
| Primary completion | 31 December 2026 |
| Estimated completion | 31 December 2026 |
| Sites | 1 location across Czechia |
Drugs / interventions tested
- Intra-articular Tranexamic acid application — full drug profile →
Conditions studied
- Blood Loss — all drugs for Blood Loss →
- Hemoglobin Change — all drugs for Hemoglobin Change →
- Blood Transfusion — all drugs for Blood Transfusion →
- Heterotopic Ossification — all drugs for Heterotopic Ossification →
Sponsor
St. Anne's University Hospital Brno, Czech Republic
Who can join
Eligibility, any sex, with Blood Loss or Hemoglobin Change. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Tranexamic acid (trans-4-aminomethyl cyclohexane carboxylic acid) is an antifibrinolytic substance that chemically belongs to the group of e-carboxylic acids. TXA is a synthetic amino acid derivative of lysine that competitively inhibits the activation of plasminogen to the serine protease, plasmin. TXA is a competitive inhibitor of tissue plasminogen activator, blocking the lysine-binding sites of plasminogen, resulting in inhibition of plasminogen activation and fibrin binding to plasminogen and therefore impairment of fibrinolysis. Due to its antifibrinolytic effect (reduction of bleeding), TXA has been recently an increasing interest in orthopaedics, especially in elective major joint replacements. The total hip arthroplasties (ΤΗΑ) are associated with perioperative blood losses exceeding 500 mL. Blood loss volumes are dependent on the chosen surgical approach and technique. Some patients that undergo elective hip replacement receive at least one blood unit in postoperative care. Heterotopic ossification is also a common complication after THA, presented as bone in soft tissue where bone normally does not appear. TXA reduces postoperative blood losses and consequently leads to less frequent blood transfusions. This has an impact on the economic burden for the health care system. Increased blood loss could lead to longer length of stay at the hospital and the connected economic consequences. TXA further reduces the incidence of heterotopic ossification after elective THA. Objectives: The aim of this study is to prospectively evaluate postoperative blood losses, hemoglobin decline and associated blood transfusion, heterotopic ossification and other parameters in patients with intraarticular application of Tranexamic acid during THA.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06903299
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Blood Loss
Currently open trials in the same condition.
- NCT07526311 — Reducing Blood Loss During Myomectomy:Uterine Artery Ligation Vs Pericervical Tourniquet · NA · recruiting
- NCT07089251 — The Perioperative Outcome of Epinephrine Infusion and Tranexamic Acid in Knee Arthroplasty Surgery · Phase 4 · recruiting
- NCT05488457 — Oxytocin Pharmacokinetics and Pharmacodynamics · Phase 2 · recruiting
- NCT06802874 — Maternal-fetal Outcomes of Genital Blood Loss Beyond 18 Weeks of Pregnancy · recruiting
- NCT05550623 — Pneumatic Tourniquet Versus no Tourniquet in Transfemoral Amputation · NA · active not recruiting
Other St. Anne's University Hospital Brno, Czech Republic trials
Trials by the same sponsor.
- NCT07315542 — Diagnostic and Therapeutic Targets in Cartilaginous Tumours · recruiting
- NCT06989229 — The Effect of Perioperative Nutritional Care on Recovery After Knee and Hip Replacement Surgery · recruiting
- NCT06579274 — Evaluation of the Safety and Efficacy of Parecoxib in Patients With Subarachnoid Hemorrhage · Phase 2 · not yet recruiting
- NCT06702059 — Cardiopulmonary Exercise Testing in Cardiosurgery Patients · recruiting
- NCT05861089 — Rest PETCO2 As a Predictor of Post-operative Complications · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06903299 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by St. Anne's University Hospital Brno, Czech Republic
- Last refreshed: 4 April 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06903299.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing